Dutch company specialised in the clinical development of therapeutic antibodies. The company sold exclusive rights to its PG-110 antibody to Abbott for $190 million. Developed by PanGenetics, PG-110 is a humanised antibody targeting nerve growth factor (in phase I clinical trials). To date, the company has raised close to €51 million in the three funding rounds completed between 2005 and 2008. The deal is an endorsement of the company’s novel strategy predicated on the development of proprietary products and the licensing of new products, excluding R&D activities.